Skip To Main Content
Hyeyoun Chang on Muck Rack

Hyeyoun Chang

As seen in: PLOS ONE, MDPI, The BMJ, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hyeyoun

Contact Hyeyoun, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Statin-dye conjugates for selective targeting of KRAS mutant cancer cells

|
By Hye-ran Moon, Zhenying Cai, Hyeyoun Chang, Seung Taek Hong
| PLOS ONE
Loading metrics Open Access Peer-reviewed Research Article Citation: Moon H-r, Cai Z, Cho BK, Chang H, Hong ST, Zhao JJ, et al. (2026) Statin-dye conjugates for selective targeting of KRAS mutant cancer cells. PLoS One 21(1): e0340189. https://doi.org/10.1371/journal.pone.0340189 Editor: Luca Pesce, Università di Pisa: Universita degli Studi di Pisa, ITALY Received: April 24, 2025; Accepted: December 17, 2025; Published: January 9, 2026 Copyright: © 2026 Moon et al.
Open in Who Shared Issue with article?

Statin-dye conjugates for selective targeting of KRAS mutant cancer cells

|
By Hye-ran Moon, Zhenying Cai, Hyeyoun Chang, Seung Taek Hong
| BioRxiv
Abstract Over 90% of pancreatic ductal adenocarcinoma (PDAC) patients involve KRAS mutations (KRASMUT), for which current treatment options are limited. Statins, commonly used to lower cholesterol, have demonstrated certain selective toxicity towards KRAS-transformed cells, prompting the question of whether statins could achieve selective uptake specifically in KRASMUT cells.
Open in Who Shared Issue with article?

14 GAS-Luc2 reporter cell lines to supersede the industrial standard of interferon-gamma ELISA for ex vivo immune activation studies and drug screening | Journal for ImmunoTherapy of Cancer

|
By Hyeyoun Chang, John G. Foulke, Luping Chen, Catherine E McManus
| The BMJ Verified
Regular and Young Investigator Award Abstracts Biomarkers, Immune Monitoring and Novel Technologies 14 GAS-Luc2 reporter cell lines to supersede the industrial standard of interferon-gamma ELISA for ex vivo immune activation studies and drug screening Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.
Open in Who Shared View Duplicates (154) Issue with article?
See all 6 articles